Silvana Novelli
@snovelli.bsky.social
📤 213
📥 295
📝 56
Hematologist.
#Lymphoma
#immunotherapy
#ITP
🏥 Institut Català d’Oncologia- Barcelona. Tap dancer 🎼
Hans IHC discrimination of Cell-of-Origin Subtype is a valid method for predicting Polatuzumab response in DLBCL
aacrjournals.org/clincancerre...
loading . . .
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
AbstractPurpose:. Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial....
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-25-2392/768346/Cell-of-Origin-Subtype-Predicts-Response-to
6 days ago
0
1
1
Should we start seeking clonal hematopoiesis before B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy?
aacrjournals.org/clincancerre...
loading . . .
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
AbstractPurpose:. Chimeric antigen receptor T cells (CAR-T) have demonstrated remarkable efficacy in multiple myeloma, but prolonged hematologic toxicity remains a common adverse event, and secondary ...
https://aacrjournals.org/clincancerres/article/31/20/4333/766064/Clonal-Hematopoiesis-and-Inflammation-Predict
6 days ago
0
2
1
reposted by
Silvana Novelli
Martine Lamy
6 days ago
#FoodInsecurity
affects
#healthcare
workers too. Efforts like
#HCWvsHunger
can help.
hcwvshunger.org
add a skeleton here at some point
0
22
14
Now it is imperative to include CLIPI in the routine evaluation of advanced stages Mycosis Fungoides & Sézary syndrome; especially when considering for alloSCT
#ctcl
ashpublications.org/blood/articl...
loading . . .
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
Key PointsThere is poor survival in advanced stage MF/SS.CLIPI stratifies patients with advanced MF/SS into risk groups for survival and has been validated
https://ashpublications.org/blood/article-abstract/146/14/1687/546197/A-new-prognostic-index-CLIPI-for-advanced?redirectedFrom=fulltext
about 1 month ago
0
1
0
reposted by
Silvana Novelli
Jack Iwashyna
about 2 months ago
Reviewing this classic article
@bmj.com
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
doi.org/10.1136/bmj....
I still teach it all the time
loading . . .
Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial
In this article by Robert Yeh and colleagues ( BMJ 2018;363:k5094, doi:10.1136/bmj.k5094), the final sentence of the Methods section should …
https://doi.org/10.1136/bmj.k5343
6
57
21
reposted by
Silvana Novelli
Vincent Rajkumar, MD
about 2 months ago
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM 5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures.
www.nejm.org/doi/abs/10.1...
0
9
3
Lo mejor de escuchar a otros especialistas es cuando te encuentras con inmunólogas como la Dra. Silvia Vidal y te da una clase de
#XPO
#selinexor
en el
#mieloma
#Hemato2025
@sehhematologia.bsky.social
about 2 months ago
0
0
1
“Manejo periquirúrgico de los pacientes con coagulopatías adquiridas inmunológicas” con Eva Mingot, un enfoque práctico.
@hospitaluvrocio.bsky.social
@sehhematologia.bsky.social
#Hemato2025
about 2 months ago
0
0
1
“Perfil molecular en la leucemia linfática crónica: más allá del TP53”.
@ferrannadeu.bsky.social
nos revela el universo de complejidad biológica de la
#LLC
@idibaps.bsky.social
@sehhematologia.bsky.social
#Hemato2025
about 2 months ago
0
2
2
Rafael de la Cámara nos revela la inmensa cantidad de fármacos antivirales en ensayo para mejorar el cuidado de nuestros pacientes.
@sehhematologia.bsky.social
#Hemato2025
about 2 months ago
0
0
1
CART de la Mano de Dr. Olalekan O. Oluwole -
#Kite
#hemato2025
@sehhematologia.bsky.social
about 2 months ago
0
0
1
Secuenciación de tercera generación en el diagnóstico hematológico. Dr. Javier Corral de la Calle repasando la evolución de la NGS.
#hemato2025
@sehhematologia.bsky.social
about 2 months ago
0
0
1
Platelet transcriptomic-powered scientific discovery in Thrombosis and Hemostasis Dr. Matthew T. Rondina Huntsman Cancer Institute & University of Utah Health, Salt Lake City, Utah (USA).
#sepsis
#inflamación
#hemato2025
❤️
about 2 months ago
0
1
1
“Selection of best donor in allogeneic stem cell transplantation: beyond HLA typing” por la Dra. Effie Wang Petersdorf
#hemato2025
#educacional
@sehhematologia.bsky.social
about 2 months ago
1
0
1
Es un lujo poder escuchar al Dr. Orfao hablando de la EMR en ls distintas neoplasias hematológicas
#Hemato2025
@sehhematologia.bsky.social
about 2 months ago
0
0
1
Administration of SUMOylation inhibitor could eradicate
#Burkitt’s
#lymphoma
treated with CD19 CAR-T.
rdcu.be/eJu9C
loading . . .
Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy
Signal Transduction and Targeted Therapy - Limited SUMOylation inhibitor administration enhances eradication of Burkitt’s lymphoma with CD19 CAR-T therapy
https://rdcu.be/eJu9C
2 months ago
0
0
1
What a beautiful work from our colleagues from Navarra!
@unav.edu
#CUN
Increasing glutamine uptake may enhance anti-tumor BCMA-CAR T-cell functionality
#MM
ashpublications.org/blood/articl...
loading . . .
Reprogramming glutamine metabolism enhances BCMA-CART cell fitness and therapeutic efficacy in multiple myeloma
Key Points. Glutamine deprivation in the tumor microenvironment might limit CAR T-cell therapeutic efficacy in cancer patients.ASCT2 overexpression improve
https://ashpublications.org/blood/article/doi/10.1182/blood.2024027496/547364/Reprogramming-glutamine-metabolism-enhances-BCMA?searchresult=1
3 months ago
0
0
1
Improved PFS with Moga-Chop for elderly ATL patients. I wonder how the Moga -Pembro would work in the same scenario 🧐
ashpublications.org/blood/articl...
loading . . .
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma
Key PointsMoga-CHOP significantly improved 1-year PFS in older patients with aggressive ATL.CCR4 mutations and Moga-associated cAEs were related to better
https://ashpublications.org/blood/article-abstract/146/12/1440/537311/A-phase-2-trial-of-CHOP-with-anti-CCR4-antibody?redirectedFrom=fulltext
3 months ago
0
0
1
🏁Avui
#bcnhop
#dansaurbana
www.barcelona.cat/barcelonacul...
loading . . .
Dansa, resistència i metàfora a l'Hop Festival | Barcelona Cultura
Sandra Egido inaugura el festival amb dues peces que fusionen el breaking i la dansa contemporània en clau crítica i poètic... Fes clic per saber-ne més!
https://www.barcelona.cat/barcelonacultura/ca/recomanem/dansa-resistencia-metafora-hop-festival
3 months ago
0
0
0
reposted by
Silvana Novelli
Kate Sears
3 months ago
🧠 Neurotoxicity in Cancer Therapy New review (Nat Rev Clin Oncol) ✅ Pathophysiology of chemo-, RT- & IO-induced neurotoxicity ✅ Clinical recognition & biomarkers ✅ Prevention & management strategies 🔍 Key messages – Cavaletti, Cámara, DeAngelis et al. Nat Rev Clin Oncol 2025
1
4
2
reposted by
Silvana Novelli
Immunity
3 months ago
loading . . .
Touch of youth: Mechanosensing expands stem-like CAR-T cells
In this issue of Immunity, Lv et al. develop a new CAR-T cell culture system that uses integrin mechanical signaling to boost CAR-T proliferation while preserving stemness, pointing out a new direction of CAR-T manufacturing.
http://dlvr.it/TN3dVz
0
2
2
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies url:
ashpublications.org/thehematolog...
loading . . .
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V22.5.202557/546918/WU-Hoo-The-Promise-of-Allogeneic-WU-CART-007-in
3 months ago
0
1
1
reposted by
Silvana Novelli
Society of Hematologic Oncology
3 months ago
Addition of lisaftoclax to myeloma regimens improved depth of response
sohoinsider.com/meetings-con...
loading . . .
lisaftoclax boosts response in mm, amyloidosis - SOHO Insider
Phase 1b/2 study shows lisaftoclax with Pd or DRd yields 61.3% ORR in relapsed MM, AL amyloidosis at SOHO 2025
https://sohoinsider.com/meetings-conferences/lisaftoclax-phase-1b-2-multiple-myeloma-amyloidosis/
0
3
2
Devimistat shows potential for a subset of BL patients, efforts should focus on improving initial therapies and exploring novel treatments for these challenging malignancies:
ashpublications.org/bloodadvance...
loading . . .
Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial
Key Points. A targeted approach to block enzymes in the TCA cycle had limited efficacy in the treatment of patients with relapsed Burkitt lymphoma.The uniq
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025016168/546236/Novel-Devimistat-Results-in-Complete-Remissions-in
3 months ago
0
0
1
reposted by
Silvana Novelli
Eric Topol
3 months ago
Fraud, using A.I., impersonating medical professionals Front page NY Times
www.nytimes.com/2025/09/05/t...
6
120
53
reposted by
Silvana Novelli
OncLive
3 months ago
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL
@societyofhemonc.bsky.social
@brownmedicine.bsky.social
#SOHO2025
#lymsm
www.onclive.com/view/mosunet...
loading . . .
Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL
A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.
https://www.onclive.com/view/mosunetuzumab-plus-polatuzumab-vedotin-triples-median-pfs-in-transplant-ineligible-lbcl
0
0
1
reposted by
Silvana Novelli
Jeffrey Perkel (he/him)
3 months ago
PS: I wrote about marimo in a larger feature on how to pick a programming language
@nature.com
:
www.nature.com/articles/d41...
loading . . .
Which programming language should I use? A guide for early-career researchers
Computer scientists and bioinformaticians address four key questions to help rookie coders to make the right choice.
https://www.nature.com/articles/d41586-025-01241-6
0
2
1
First-ever comparison between haplo-HSCT using modified post-transplantation cyclophosphamide and combined IST+EPAG.
www.astctjournal.org/article/S266...
loading . . .
Comparison of haploidentical-hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide and eltrombopag combined with immunosuppression for the treatment of severe ap...
Severe aplastic anemia (SAA) is a life-threatening disease mainly caused by abnormal immune function in the form of T lymphocyte hyperfunction 1. SAA and very SAA (VSAA) can be treated with human leuk...
https://www.astctjournal.org/article/S2666-6367(25)01331-4/abstract
4 months ago
0
2
1
I suppose MRD would help explain why the indirect comparison of Epco vs Odro shows a benefit for Epco, despite having a lower CRR (but higher ORR)
ashpublications.org/bloodadvance...
loading . . .
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Key PointsIn this indirect comparison, epcoritamab significantly improved response and survival vs CIT in patients with relapsed or refractory third-line o
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024015274/537623/Indirect-comparison-of-epcoritamab-vs
4 months ago
0
0
1
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis, regardless of MGUS status, amazing work!:
ashpublications.org/bloodadvance...
loading . . .
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis
TO THE EDITOR:
https://ashpublications.org/bloodadvances/article/9/15/3766/537151/Dysregulated-immune-proteins-in-plasma-in-the-UK
4 months ago
0
1
3
reposted by
Silvana Novelli
Trends in Immunology
5 months ago
Development of a circadian immune system
#immunology
loading . . .
Development of a circadian immune system
Circadian rhythms are key regulators of immune functions. These endogenous oscillations help to maintain immune homeostasis, regulate responses to pathogens, and shape vaccine efficacy. Recent studies further indicate that they are of clinical relevance for cancer immunotherapies. While circadian immune rhythms are thus recognized to be important in adults, it is unknown at what developmental stage these rhythms begin to manifest. In this opinion article we review the development of circadian rhythms in the immune system in both rodents and humans, with a focus on their interactions during the perinatal period. Understanding their emergence in early life may help guide time-based clinical interventions for infants.
http://dlvr.it/TLtbwJ
0
2
1
reposted by
Silvana Novelli
STITCHES Medicine - the Best of Medical Research
6 months ago
Mindfulness and Tai Chi effectively enhance mood in cancer survivors, regardless of participants' intervention preferences. by Carlson LE, Jones JM (...) Speca M et 5 al. in J Clin Oncol
#MedSky
👉 get more
here
📖 read the article:
https://ascopubs.org/doi/10.1200/JCO-24-02540
0
9
1
reposted by
Silvana Novelli
Blood Journals Portfolio
6 months ago
For patients who receive allo-HCT, socioeconomic barriers have a less pronounced impact on mortality.
buff.ly/8wTlcIF
#hemesky
#AML
0
2
1
Harmful but effective!
ashpublications.org/bloodneoplas...
loading . . .
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
Key PointsThe combination of rhIL-15 and mogamulizumab is associated with immunologic toxicity.NK cell activity increases within days of treatment and is a
https://ashpublications.org/bloodneoplasia/article/2/1/100054/525853/A-phase-1-study-of-interleukin-15-in-combination
6 months ago
0
0
0
reposted by
Silvana Novelli
NPR
6 months ago
In dire situations, stress can make us panic and impair our ability to make lifesaving decisions. Emergency response professionals share the tactics they use to stay cool and collected on the job.
loading . . .
COMIC: Don't panic! 6 strategies to keep you calm in a crisis
In dire situations, stress can make us panic and impair our ability to make lifesaving decisions. Emergency response professionals share the tactics they use to stay cool and collected on the job.
https://n.pr/43O43VV
11
453
122
Re-abriendo el melón de los péptidos derivados del timo y la respuesta inmune post tph.
www.sciencedirect.com/science/arti...
loading . . .
Thymic peptides in immune reconstitution and clinical outcome after allogeneic hematopoietic cell transplantation
Patients with hematologic malignancies or nonmalignant diseases may undergo allogeneic hematopoietic cell transplantation (HCT), which represents a po…
https://www.sciencedirect.com/science/article/pii/S2950328025000251
6 months ago
0
0
1
reposted by
Silvana Novelli
Alberto Mussetti
6 months ago
Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions url:
ashpublications.org/blood/articl...
0
1
1
reposted by
Silvana Novelli
Alberto Mussetti
6 months ago
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma | New England Journal of Medicine
www.nejm.org/doi/full/10....
loading . . .
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma | NEJM
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous...
https://www.nejm.org/doi/full/10.1056/NEJMoa2505133?query=RP
0
2
1
reposted by
Silvana Novelli
JAMA Oncology
6 months ago
Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare.
#ASCO25
@ascocancer.bsky.social
ja.ma/3FCoVHI
1
17
11
reposted by
Silvana Novelli
NEJM.org
6 months ago
Late breaking at
#ASCO25
: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial:
nej.md/4mh5RPL
@ascocancer.bsky.social
2
50
33
reposted by
Silvana Novelli
Sara R. Fagerlie, PhD, CHCP
6 months ago
Durable reponses with Allo-316 allogeneic CD70 CAR T-cell therapy in advanced clear cell RCC presented by Dr Srour at
#ASCO25
phase 1b TRAVERSE study
#RCCsm
#cansky
#oncsky
0
4
2
reposted by
Silvana Novelli
American Society of Hematology
7 months ago
In this episode of The Hematologist podcast, Dr. Michael Scott talks with Dr. Marc Michel about long-term follow-up of the STOPAGO study, which focuses on the use of thrombopoietin receptor agonists on patients with immune thrombocytopenia. Listen now:
ashpublications.org/...
#HemeSky
#MedSky
loading . . .
0
2
1
reposted by
Silvana Novelli
STITCHES Medicine - the Best of Medical Research
7 months ago
CNS border tissues facilitate immune communication, enhancing surveillance and protection without isolating the central nervous system. by Smyth LCD and Kipnis J in Nat Rev Immunol
#MedSky
👉 get more
here
📖 read the article:
loading . . .
Redefining CNS immune privilege - Nature Reviews Immunology
In this Perspective, Smyth and Kipnis reappraise the concept of immune privilege in the central nervous system. Although immune privilege was originally thought to involve isolation of the central nervous system from the peripheral immune system, the authors argue that it is instead a special immunological state that involves continuous neuroimmune dialogue.
https://www.nature.com/articles/s41577-025-01175-0
0
12
7
reposted by
Silvana Novelli
Alberto Mussetti
7 months ago
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | New England Journal of Medicine
www.nejm.org/doi/abs/10.1...
loading . . .
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...
https://www.nejm.org/doi/abs/10.1056/NEJMoa2408771
0
1
1
How can we better understand DLBCL? This new neural network, DLBclass, tackles this by assigning almost all cases to their C1-C5 genetic subtypes, unlocking valuable genetic information.
#translationalresearch
#hematology
#deeplearning
ashpublications.org/blood/articl...
loading . . .
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma
Key PointsWe developed a neural network–based probabilistic classifier, DLBclass, that assigns each DLBCL to its respective C1-C5 genetic subtype.DLBclass
https://ashpublications.org/blood/article/145/18/2041/534607/DLBclass-a-probabilistic-molecular-classifier-to
7 months ago
0
1
1
www.sciencedirect.com/science/arti...
loading . . .
The Role of Radiation Therapy for Palliation of Hematologic Malignancies
Palliative RT is an effective tool in management and treatment of patients with hematologic malignancies. Even relatively low doses of palliative RT c…
https://www.sciencedirect.com/science/article/abs/pii/S1053429624000857
8 months ago
0
2
0
reposted by
Silvana Novelli
Jeff Saucerman
8 months ago
Terrific paper by post-doc
@aclark.bsky.social
in
@plos.org
Comp Biol. This tutorial enables students and biologists to simulate biological networks with our tool Netflux, no programming required!
#sysbio
#cardiosky
🧪
add a skeleton here at some point
1
31
8
reposted by
Silvana Novelli
Alberto Mussetti
8 months ago
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
authors.elsevier.com/a/1ks1w5EIIg...
loading . . .
https://authors.elsevier.com/a/1ks1w5EIIgPexk
0
2
2
reposted by
Silvana Novelli
HematoRules
8 months ago
🚨 NEW
#ICOnic
PUBLICATION 🚨 Congratulations
@martape28.bsky.social
et al. For this paper! Now available online ⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
www.nature.com/articles/s41...
loading . . .
Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC - Bone Marrow Transp...
Bone Marrow Transplantation - Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on...
https://www.nature.com/articles/s41409-025-02559-5
0
1
2
Relevant👇🏼👇🏼👇🏼👇🏼👇🏼
add a skeleton here at some point
8 months ago
0
0
0
Load more
feeds!
log in
